Quick Answer
Walnut Lipid Profile Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Although several clinical trials have examined their impact on the lipid profile, results have been inconsistent, and evidence regarding their effects on apolipoproteins is limited.
Key Takeaways
- 01Although several clinical trials have examined their impact on the lipid profile, results have been inconsistent, and evidence regarding their effects on apolipoproteins is limited. [Mashayekhi G (2026)]
- 02The pooled analysis of 49 RCTs (57 effect sizes; 4611 participants) showed that Walnut consumption significantly reduced and TG (WMD: -6.24 mg/dL, 95% CI: [-9.49, -2.99], p p p p = 0.145), Apo-A1 (WMD: 0.0, 95% CI: [-0.01, 0.00], p = 0.573), or Apo-B (WMD: 0.1, 95% CI: [-0.02, 0.05], p = 0.462). [Mashayekhi G (2026)]
- 03In conclusion, walnut supplementation improves the lipid profile by significantly lowering TC, LDL-C, and TG levels. [Mashayekhi G (2026)]
- 04Walnuts ( Juglans regia L.) are rich in polyunsaturated fatty acids (PUFAs), fiber, and bioactive compounds that may positively affect lipid metabolism. [Mashayekhi G (2026)]
The current Migaku evidence database contains 1 reusable source document for Walnut Lipid Profile Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove.
- Although several clinical trials have examined their impact on the lipid profile, results have been inconsistent, and evidence regarding their effects on apolipoproteins is limited. [Mashayekhi G (2026); evidence level 1]
- The pooled analysis of 49 RCTs (57 effect sizes; 4611 participants) showed that Walnut consumption significantly reduced and TG (WMD: -6.24 mg/dL, 95% CI: [-9.49, -2.99], p p p p = 0.145), Apo-A1 (WMD: 0.0, 95% CI: [-0.01, 0.00], p = 0.573), or Apo-B (WMD: 0.1, 95% CI: [-0.02, 0.05], p = 0.462). [Mashayekhi G (2026); evidence level 1]
- In conclusion, walnut supplementation improves the lipid profile by significantly lowering TC, LDL-C, and TG levels. [Mashayekhi G (2026); evidence level 1]
- Walnuts ( Juglans regia L.) are rich in polyunsaturated fatty acids (PUFAs), fiber, and bioactive compounds that may positively affect lipid metabolism. [Mashayekhi G (2026); evidence level 1]
Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording.
This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.
Sources